1. (1999) Note for guidance on quality of modified release products: a oral dosage forms, B: transdermal dosage forms section 1 (Quality), in, European Medicines Agency Committee for Proprietary Medicinal Products.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003664.pdf
2. (2010) European Medicines Agency concludes review of modified-release oral opioids of the WHO level III scale for the management of pain (Press Release)
3. (2011) Effect of Alcohol on the Drug Dissolution Properties of Tablets Formulated with Carbopol®* Polymers, Lubrizol Technical Data Sheet 793.
4. (2014) Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1). in, Committee for Medicinal Products for Human Use (CHMP).
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/11/WC500177884.pdf
5. (2012) The DAWN Report: highlights of the 2010 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits, in: (SAMSHA) Center for Behavioral Health Statistics and Quality, Rockville, MD.
https://www.samhsa.gov/data/sites/default/files/DAWN096/DAWN096/SR096EDHighlights2010.pdf